专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007030708A2 ANTIMICROBIAL ADZYMES AND USES THEREOF 审中-公开
标题翻译：抗微生物药物及其用途
公开(公告)号：WO2007030708A2
公开(公告)日：2007-03-15
申请号：PCT/US2006/035011
申请日：2006-09-08
申请人： ADNEXUS THERAPEUTICS, INC. , AFEYAN, Noubar, B. , LEE, Frank, D. , WONG, Gordon, G. , DAS GUPTA, Ruchira
发明人： AFEYAN, Noubar, B. , LEE, Frank, D. , WONG, Gordon, G. , DAS GUPTA, Ruchira
CPC分类号： C12N9/6427 , C07K14/70578 , C07K14/7151 , C07K16/1018 , C07K16/241 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C07K2319/01 , C12N9/6429 , C12N9/6491 , C12Y304/21005
摘要： Disclosed is a family of novel protein constructs, useful as antimicrobial agents, termed "adzymes," comprising an address moiety and a catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as an infectious disease.
摘要翻译：公开了一种新颖的蛋白质构建体，其可用作抗微生物剂，称为“腺苷”，其包含地址部分和催化结构域。本发明还提供了包含这些腺病，制造腺体的方法，DNA编码腺病或其部分的药物组合物和使用腺病的方法，例如用于治疗患有疾病如感染性疾病的人类受试者。

2. 发明申请

WO2004019878A2 ADZYMES AND USES THEREOF 审中-公开
标题翻译： ADZYMES及其用途
公开(公告)号：WO2004019878A2
公开(公告)日：2004-03-11
申请号：PCT/US2003/026937
申请日：2003-08-27
申请人： COMPOUND THERAPEUTICS, INC. , AFEYAN, Noubar, B. , BAYNES, Brian , DASGUPTA, Ruchira , LEE, Frank, D. , WONG, Gordon, G.
发明人： AFEYAN, Noubar, B. , BAYNES, Brian , DASGUPTA, Ruchira , LEE, Frank, D. , WONG, Gordon, G.
IPC分类号： A61K
CPC分类号： C12N15/62 , A61K47/6425 , A61K47/6839 , A61K47/6843 , A61K47/6849 , C07K2319/00 , C07K2319/01 , C12N9/00 , C12N9/50
摘要： Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. In some types of disclosed adzymes, the address binds with a binding site on or in functional proximity to a targeted biomolecule, e.g., an extracellular targeted biomolecule, and is disposed adjacent the catalytic domain so that its affinity serves to confer anew specificity to the catalytic domain by increasing the effective local concentration of the target in the vicinity of the catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as a disease associated with a soluble or membrane bound molecule, e.g., an allergic or inflammatory disease.
摘要翻译：公开了一种新型蛋白质构建体家族，其用作药物和用于其它目的，称为“腺苷”，包括地址部分和催化结构域。在一些类型的所公开的腺病毒中，该地址与靶向生物分子例如细胞外靶向生物分子或功能接近的结合位点结合，并且设置在催化结构域附近，使得其亲和力用于赋予催化剂新的特异性通过增加靶在催化结构域附近的有效局部浓度。本发明还提供药物组合物，其包含这些腺病，制造腺体的方法，编码DNA的DNA或其部分，以及使用腺病的方法，例如用于治疗患有疾病例如与可溶性或膜相关的疾病的人类受试者结合分子，例如过敏性或炎性疾病。

3. 发明申请

WO2008060610A3 SYSTEMIC ADMINISTRATION OF COLONY STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISORDERS 审中-公开
标题翻译：系统管理集落刺激因子治疗淀粉样变性相关性疾病
公开(公告)号：WO2008060610A3
公开(公告)日：2008-12-04
申请号：PCT/US2007024055
申请日：2007-11-16
申请人： BIOGEN IDEC INC , WONG GORDON , RELTON JANE K
发明人： WONG GORDON , RELTON JANE K
IPC分类号： A61K38/00
CPC分类号： A61K38/193
摘要： The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by systemic administration of a colony stimulating factor. For example, the activity of bone marrow-derived microglial cells in an organ or tissue can be increased by systemic administration of a colony stimulating factor, particularly macrophage colony stimulating factor, either alone or in combination with additional colony stimulating factors, stem cell factors or other compounds capable of treating amyloidosis.
摘要翻译：本发明涉及通过增加需要通过系统施用集落刺激因子治疗的动物的器官或组织中的组织驻留巨噬细胞活性来治疗淀粉样变性，与淀粉样斑块形成相关的疾病和病症（例如阿尔茨海默氏病）的方法。例如，可以通过单独或与其他集落刺激因子，干细胞因子或其组合的系统性施用集落刺激因子，特别是巨噬细胞集落刺激因子来增加器官或组织中骨髓来源的小神经胶质细胞的活性其他能够治疗淀粉样变性的化合物。

4. 发明申请

WO2008060610A2 SYSTEMIC ADMINISTRATION OF COLONY STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISORDERS 审中-公开
标题翻译：组织刺激因子的系统治疗以治疗淀粉样相关疾病
公开(公告)号：WO2008060610A2
公开(公告)日：2008-05-22
申请号：PCT/US2007/024055
申请日：2007-11-16
申请人： BIOGEN IDEC MA INC. , WONG, Gordon
发明人： WONG, Gordon
IPC分类号： A61K38/19
CPC分类号： A61K38/193
摘要： The invention relates a method of treating amyloidosis, diseases and disorders associated with amyloid plaque formation, e.g., Alzheimer's disease by increasing tissue resident macrophage activity in an organ or tissue of an animal requiring treatment by systemic administration of a colony stimulating factor. For example, the activity of bone marrow-derived microglial cells in an organ or tissue can be increased by systemic administration of a colony stimulating factor, particularly macrophage colony stimulating factor, either alone or in combination with additional colony stimulating factors, stem cell factors or other compounds capable of treating amyloidosis.
摘要翻译：本发明涉及一种通过增加需要通过系统性施用集落刺激因子治疗的动物的器官或组织中的组织驻留巨噬细胞活性来治疗淀粉样变性疾病，与淀粉样蛋白斑形成相关的疾病和病症的方法，例如阿尔茨海默氏病。例如，可通过全身施用集落刺激因子，特别是巨噬细胞集落刺激因子，单独或与额外的集落刺激因子，干细胞因子或组合刺激因子组合来增加骨髓来源的小胶质细胞在器官或组织中的活性能够治疗淀粉样变性的其他化合物。

5. 发明申请

WO2007030708A3 ANTIMICROBIAL ADZYMES AND USES THEREOF 审中-公开
标题翻译：抗微生物药物及其用途
公开(公告)号：WO2007030708A3
公开(公告)日：2008-01-17
申请号：PCT/US2006035011
申请日：2006-09-08
申请人： ADNEXUS THERAPEUTICS INC , AFEYAN NOUBAR B , LEE FRANK D , WONG GORDON G , DAS GUPTA RUCHIRA
发明人： AFEYAN NOUBAR B , LEE FRANK D , WONG GORDON G , DAS GUPTA RUCHIRA
IPC分类号： C07K14/435
CPC分类号： C12N9/6427 , C07K14/70578 , C07K14/7151 , C07K16/1018 , C07K16/241 , C07K2317/21 , C07K2317/34 , C07K2317/622 , C07K2319/00 , C07K2319/01 , C12N9/6429 , C12N9/6491 , C12Y304/21005
摘要： Disclosed is a family of novel protein constructs, useful as antimicrobial agents, termed "adzymes," comprising an address moiety and a catalytic domain. The present invention also provides pharmaceutical compositions comprising these adzymes, methods of making adzymes, DNA's encoding adzymes or parts thereof, and methods of using adzymes, such as for treating human subjects suffering from a disease, such as an infectious disease.
摘要翻译：公开了一种新颖的蛋白质构建体，其可用作抗微生物剂，称为“腺苷”，其包含地址部分和催化结构域。本发明还提供了包含这些腺病，制造腺体的方法，DNA编码腺病或其部分的药物组合物和使用腺病的方法，例如用于治疗患有疾病如感染性疾病的人类受试者。

6. 发明申请

WO1990001352A1 IMPROVED NEEDLE-LESS PARENTERAL FLUID INJECTOR 审中-公开
标题翻译：改进的无针孔流体注射器
公开(公告)号：WO1990001352A1
公开(公告)日：1990-02-22
申请号：PCT/US1989003308
申请日：1989-07-31
申请人： LOO, George, D., H. , WONG, Gordon, A.
IPC分类号： A61M31/00
CPC分类号： A61M39/02
摘要： A fluid injector (20) for use with a needle-less syringue (26) or needle-less add-on IV line (28) is disclosed. The injector is connected to a main IV line (10) and has a fluid passageway (34) from the syringue or the add-on IV set (28) to the main IV line. The injector comprises an anti-backflow valve member (42) where the member is movable under fluid pressure alone between a first position where the fluid can flow through the injector and a second position where the fluid cannot flow through the injector. The injector (20) also comprises a valve (32) located near the syringe end of the injector for receiving the fluid from the syringue of the add-on IV line for injection into the main IV line (10) and for preventing air embolus entering into the IV line (10).
摘要翻译：公开了一种用于无针注射器（26）或无针附件IV管线（28）的流体注射器（20）。注射器连接到主IV管线（10）并且具有从注射器或附加IV组件（28）到主IV管线的流体通道（34）。喷射器包括防回流阀构件（42），其中构件可以在流体可以流过喷射器的第一位置和流体不能流过喷射器的第二位置之间单独在流体压力下移动。注射器（20）还包括位于注射器的注射器末端附近的阀（32），用于从用于注入主IV管线（10）的附加IV线的注射器接收流体，并且用于防止空气栓塞进入进入IV线（10）。

7. 发明申请

WO2022159575A1 CTLA4-BINDING PROTEINS AND METHODS OF TREATING CANCER 审中-公开
公开(公告)号：WO2022159575A1
公开(公告)日：2022-07-28
申请号：PCT/US2022/013120
申请日：2022-01-20
申请人： BIOENTRE LLC , WONG, Gordon, Gokleun , LING, Vincent
发明人： WONG, Gordon, Gokleun , LING, Vincent
IPC分类号： A61P35/00 , C07K16/28 , A61K39/00
摘要： The present disclosure provides engineered antigen-binding proteins that bind to cytotoxic T-lymphocyte-associated antigen-4 (CTLA4). Nucleic acids, vectors, host cells, and conjugates are also provided herein. Further provided are kits and pharmaceutical compositions comprising said entities as well as methods of making the engineered antigen-binding proteins and methods of treating a subject in need thereof.

8. 发明申请

WO2005085430A3 ADZYMES AND USES THEREOF 审中-公开
标题翻译： ADZYMES及其用途
公开(公告)号：WO2005085430A3
公开(公告)日：2006-07-20
申请号：PCT/US2005006976
申请日：2005-03-02
申请人： COMPOUND THERAPEUTICS INC , WONG GORDON G , AFEYAN NOUBAR B , LEE FRANK D , DAS GUPTA RUCHIRA , BAYNES BRIAN , CAMPHAUSEN RAY
发明人： AFEYAN NOUBAR B , LEE FRANK D , DAS GUPTA RUCHIRA , BAYNES BRIAN , CAMPHAUSEN RAY
IPC分类号： C07K19/00 , A61K38/48 , C12N1/16 , C12N1/20 , C12N5/10 , C12N9/00 , C12N9/50 , C12N9/76 , C12N15/52 , C12N15/62
CPC分类号： C12N9/6427 , C07K2319/00 , C07K2319/01 , C07K2319/33 , C12N9/00 , C12N9/50 , C12N15/62
摘要： Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. A preferred adzyme is one having a catalytic domain based on mesotrypsin (including functional fragments, derivatives, variants, homologs, and/or stabilized mutations thereof). Another preferred adzyme is one having a targeting moiety based on a protein scaffold, such a protein having an immunoglobulin-like fold.
摘要翻译：公开了一种新型蛋白质构建体家族，其用作药物和用于其它目的，称为“腺苷”，包括地址部分和催化结构域。优选的酶是具有基于胰蛋白酶的催化结构域（包括功能片段，衍生物，变体，同源物和/或其稳定突变）的酶。另一个优选的酶是具有基于蛋白质支架的靶向部分，如具有免疫球蛋白样折叠的蛋白质。

9. 发明申请

WO2005085430A2 ADZYMES AND USES THEREOF 审中-公开
标题翻译： ADZYMES及其用途
公开(公告)号：WO2005085430A2
公开(公告)日：2005-09-15
申请号：PCT/US2005/006976
申请日：2005-03-02
申请人： COMPOUND THERAPEUTICS, INC. , WONG, Gordon, G. , AFEYAN, Noubar, B. , LEE, Frank, D. , DAS GUPTA, Ruchira , BAYNES, Brian , CAMPHAUSEN, Ray
发明人： AFEYAN, Noubar, B. , LEE, Frank, D. , DAS GUPTA, Ruchira , BAYNES, Brian , CAMPHAUSEN, Ray
IPC分类号： C12N9/00
CPC分类号： C12N9/6427 , C07K2319/00 , C07K2319/01 , C07K2319/33 , C12N9/00 , C12N9/50 , C12N15/62
摘要： Disclosed is a family of novel protein constructs, useful as drugs and for other purposes, termed "adzymes," comprising an address moiety and a catalytic domain. A preferred adzyme is one having a catalytic domain based on mesotrypsin (including functional fragments, derivatives, variants, homologs, and/or stabilized mutations thereof). Another preferred adzyme is one having a targeting moiety based on a protein scaffold, such a protein having an immunoglobulin-like fold.
摘要翻译：公开了一种新型蛋白质构建体，其可用作药物和用于其它目的，称为“腺苷”，其包含地址部分和催化结构域。优选的酶是具有基于胰蛋白胨的催化结构域（包括功能片段，衍生物，变体，同源物和/或其稳定的突变）的酶。另一个优选的酶是具有基于蛋白质支架的靶向部分的酶，这种蛋白质具有免疫球蛋白样折叠。

10. 发明申请

WO0065052A9 BRIDGE-1, A TRANSCRIPTION FACTOR 审中-公开
标题翻译： BRIDGE-1，转录因子
公开(公告)号：WO0065052A9
公开(公告)日：2002-06-20
申请号：PCT/US0010616
申请日：2000-04-21
申请人： HABENER JOEL F , THOMAS MELISSA K , WONG GORDON G , YAO KWOK-MING
发明人： HABENER JOEL F , THOMAS MELISSA K , WONG GORDON G , YAO KWOK-MING
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N15/12 , A61K38/17 , C07K16/18 , G01N33/68
CPC分类号： C07K14/4705 , A61K38/00 , A61K48/00
摘要： The present invention concerns a transcription factor, Bridge-1. More specifically, isolated nucleic acid molecules are provided encoding Bridge-1. Recombinant methods for making Bridge-1 polypeptides are also provided as are Bridge-1 antibodies. Screening methods are also provided for identifying polypeptides that bind to Bridge-1 or a Bridge-1 fragment, such as a fragment containing PDZ-like binding domain of Bridge-1.
摘要翻译：本发明涉及转录因子Bridge-1。更具体地，提供编码Bridge-1的分离的核酸分子。 Bridge-1多肽的重组方法也是Bridge-1抗体。还提供了筛选方法用于鉴定结合Bridge-1或Bridge-1片段的多肽，例如含有Bridge-1的PDZ样结合结构域的片段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式